Methods of treating melanoma
View Patent ↗The present disclosure is directed to methods of treating malignant melanoma by irradiating sites to which melanoma cells have become locally advanced, surgically undesirable, or have metastasized. In various embodiments of the invention, patients are treated with radiation doses in amounts ranging from about 25 to 230 cGy, preferably about 100 cGy to about 200 cGy, at least twice a day. The treatment regimen can be performed in the absence of additional treatments for the metastatic melanoma (e.g., chemotherapy/targeted therapy/immunotherapy) or in combination with additional therapies for chemotherapy/targeted therapy/immunotherapy. Various additional embodiments relate to the administration of between 20 and 100 fractions of radiation, preferably between 20 and 56 fractions of radiation.
1. A method for treating malignant melanoma in a subject comprising irradiating malignant melanoma within the subject with at least two fractions of radiation per day, said fractions of radiation being between about 100 to about 160 centiGray (cGy) and said fractions being separated by a time interval of at least about 0.5 hour.
2. The method according to claim 1 , wherein the fractions of radiation are separated by a time interval ranging from about 1 hour and, maximally, about 23 hours.
3. The method according to claim 1 , wherein the fractions of radiation are separated by a time interval ranging from about 1 hour and about 8 hours.
4. The method according to claim 1 , wherein the fractions of radiation are separated by a time interval ranging from about 2 hours and about 8 hours.
5. The method according to claim 1 , wherein the fractions of radiation are separated by a time interval ranging from about 1 hour and about 6 hours.
6. The method according to claim 1 , said method comprising treating said subject with radiation and a therapy comprising surgery, chemotherapy, targeted immunotherapy, immunotherapy or a combination of said therapies.
7. The method according to claim 6 , wherein said chemotherapy, targeted immunotherapy or immunotherapy is selected from treatment with vemurafenib, dabrafenib, trametinib, cobimetinib, temozolomide, dacarbazine, paclitaxel or combinations thereof.
8. The method according to claim 7 , wherein said subject is treated with a total of between 20 and 100 fractions of radiation.
9. The method according to claim 8 , wherein said subject is treated with a total of between 20 and 56 fractions of radiation.
10. The method according to claim 6 , wherein said chemotherapy, targeted immunotherapy or immunotherapy is selected from treatment with pembrolizumab, ipilmumab, nivolumab, interferon alpha, interferon alpha 2b or combinations thereof.
11. The method according to claim 10 , wherein said subject is treated with a total of between 20 and 100 fractions of radiation.
12. The method according to claim 11 , wherein said subject is treated with a total of between 20 and 56 fractions of radiation.
13. The method according to claim 6 , wherein said subject is treated with a total of between 20 and 100 fractions of radiation.
14. The method according to claim 13 , wherein said subject is treated with a total of between 20 and 56 fractions of radiation.
15. The method according to claim 1 , wherein said subject is treated with a total of between 20 and 100 fractions of radiation.
16. The method according to claim 15 , wherein said subject is treated with a total of between 20 and 56 fractions of radiation.
17. The method according to claim 1 , said method comprising irradiating malignant melanoma within the subject with at least two fractions of radiation per day, said fractions of radiation being between about 100 to about 135 centiGray (cGy) and said fractions being separated by a time interval of at least about 0.5 hour.